Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senator Wants US Government To Make Generics

Executive Summary

Public manufacturing of generics would drive down prices and alleviate shortages, according to legislation tabled by US Democratic Senator Elizabeth Warren.

You may also be interested in...



California Plans To Create Own Generics Label

California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

UK Industry Is Puzzled By State-Ownership Proposal

Plans unveiled by the UK’s main opposition party to set up a publicly-owned generics manufacturer fail to recognize the benefits and savings created through multisource competition, the country’s generics industry believes.

Leaks And Prejudice Must End In US Multi-State Pricing Case

A host of leading generics firms have banded together to call for an order to prevent leaks and potentially harmful public allegations, as they confront ongoing multi-district litigation over generics pricing in the US.

Topics

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel